{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T07:05:58Z","timestamp":1794899158435,"version":"4.9.1"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Restoring apoptotic cell death is a critical goal for cancer therapy. One of the primary mechanisms by which cancer cells evade death and maintain survival in the face of stress signals is by overexpression of prosurvival B-cell lymphoma 2 (BCL2) family members such as BCL2, BCL-xL, and MCL1, which suppress the intrinsic (mitochondrial) pathway of apoptosis through complex protein and membrane interactions. While these antiapoptotic proteins have been validated as potent therapeutic targets, synthesis of their inhibitors remained challenging for decades mainly due to the presence of a difficult to target, highly hydrophobic groove on the surface. The groove serves as a binding site for the BH3 domain of corresponding proapoptotic partners, which leads to their sequestration and prevents apoptosis. In 2008, a Cancer Research article by Tse and colleagues, led by Dr. Steven Elmore from Abbott Laboratories, reported the discovery of the first orally bioavailable BCL2\/BCL-xL inhibitor, navitoclax (ABT-263), marking the onset of an era of \u201cBH3 mimetics\u201d in cancer therapeutics and changing the therapeutic landscape especially for leukemia. Here, we reflect on how this landmark study fueled development of small-molecule BH3 mimetics like venetoclax and seek to indicate new strategies and future directions for improving the clinical activity of navitoclax for hematologic malignancies.<\/jats:p>\n                  <jats:p>See related article by Tse and colleagues, Cancer Res 2008;68:3421\u20133428.<\/jats:p>","DOI":"10.1158\/0008-5472.can-23-2804","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T13:03:05Z","timestamp":1697115785000},"page":"3501-3503","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["BCL-xL Targeting to Induce Apoptosis and to Eliminate Chemotherapy-Induced Senescent Tumor Cells: From Navitoclax to Platelet-Sparing BCL-xL PROTACs"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0979-026X","authenticated-orcid":false,"given":"Anna","family":"Skwarska","sequence":"first","affiliation":[{"name":"1Department of Oncology, Albert Einstein College of Medicine, The Bronx, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[{"name":"1Department of Oncology, Albert Einstein College of Medicine, The Bronx, New York."},{"name":"2Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY."},{"name":"3Departmenf of Leukemia, MD Anderson Cancer Center, The University of Texas, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"2023110107300598200_bib1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/2159-8290.CD-17-0797","article-title":"Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax","volume":"12","author":"Leverson","year":"2017","journal-title":"Cancer Discov"},{"key":"2023110107300598200_bib2","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"2023110107300598200_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"2023110107300598200_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"2","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2023110107300598200_bib5","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023110107300598200_bib6","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"2023110107300598200_bib7","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"12","author":"Khan","year":"2019","journal-title":"Nat Med"},{"key":"2023110107300598200_bib8","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/2159-8290.CD-20-1375","article-title":"Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence","volume":"11","author":"Duy","year":"2021","journal-title":"Cancer Discov"},{"key":"2023110107300598200_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nm.4010","article-title":"Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice","volume":"22","author":"Chang","year":"2016","journal-title":"Nat Med"},{"key":"2023110107300598200_bib10","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.3324\/haematol.2022.281915","article-title":"Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells","volume":"108","author":"Jia","year":"2023","journal-title":"Haematologica"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-23-2804\/3372541\/can-23-2804.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/21\/3501\/3376582\/3501.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/21\/3501\/3376582\/3501.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T03:30:24Z","timestamp":1698809424000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/21\/3501\/729709\/BCL-xL-Targeting-to-Induce-Apoptosis-and-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":10,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,10,12]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-23-2804","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]}}}